What’s in Metabolomics for Alcoholic Liver Disease?

Suciu, A; Crişan, Dana; Procopeţ, Bogdan; Radu, Corina; Socaciu, Carmen; Tanţău, Marcel; Ştefănescu, Horia; Grigorescu, Mircea

doi:10.15403/jgld.2014.1121.271.ald

Cited by 13 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both total and free cholesterol were increased two-fold in the liver [60]. Metabolomics has identified specific lipids in serum that were associated with alcohol-induced liver diseases, specifically, N-lauroylglycine identified cirrhosis with 100% sensitivity and 90% specificity, while decatrienoic acid could evaluate liver disease severity with 100% sensitivity and specificity [61].…”

Section: Alcoholic Liver Disease (Ald)mentioning

confidence: 99%

Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy

Beyoğlu

Idle

2020

Metabolites

View full text Add to dashboard Cite

In recent years, there has been a plethora of attempts to discover biomarkers that are more reliable than α-fetoprotein for the early prediction and prognosis of hepatocellular carcinoma (HCC). Efforts have involved such fields as genomics, transcriptomics, epigenetics, microRNA, exosomes, proteomics, glycoproteomics, and metabolomics. HCC arises against a background of inflammation, steatosis, and cirrhosis, due mainly to hepatic insults caused by alcohol abuse, hepatitis B and C virus infection, adiposity, and diabetes. Metabolomics offers an opportunity, without recourse to liver biopsy, to discover biomarkers for premalignant liver disease, thereby alerting the potential of impending HCC. We have reviewed metabolomic studies in alcoholic liver disease (ALD), cholestasis, fibrosis, cirrhosis, nonalcoholic fatty liver (NAFL), and nonalcoholic steatohepatitis (NASH). Specificity was our major criterion in proposing clinical evaluation of indole-3-lactic acid, phenyllactic acid, N-lauroylglycine, decatrienoate, N-acetyltaurine for ALD, urinary sulfated bile acids for cholestasis, cervonoyl ethanolamide for fibrosis, 16α-hydroxyestrone for cirrhosis, and the pattern of acyl carnitines for NAFL and NASH. These examples derive from a large body of published metabolomic observations in various liver diseases in adults, adolescents, and children, together with animal models. Many other options have been tabulated. Metabolomic biomarkers for premalignant liver disease may help reduce the incidence of HCC.

show abstract

Section: Alcoholic Liver Disease (Ald)mentioning

confidence: 99%

Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy

Beyoğlu

Idle

2020

Metabolites

View full text Add to dashboard Cite

show abstract

“…In this small pilot study, five metabolites were statistically different between the cirrhotic patients and controls, whereas three additional metabolites were marginally significant. These candidates included N-lauroglycine and TUDCA, two metabolites that have also been reported in metabolite profiling studies of the systemic circulation in patients with cirrhosis (7,11,14). Because the proposed approach is based on a series of prospectively defined rational criteria about the pre-and posthepatic concentration levels of each metabolite, the proposed approach may provide a way to refine and focus on specific candidate biomarkers and to offer more confidence in their clinical utility.…”

Section: G586mentioning

confidence: 99%

Endoscopic ultrasound-guided sampling and profiling of portal circulation in human patients for metabolic research studies and biomarker assessment

Ryou

Stylopoulos

2020

American Journal of Physiology-Gastrointestinal and Liver Physi

View full text Add to dashboard Cite

Portal and hepatic circulation can now be safely accessed using endoscopic ultrasound (EUS). EUS-guided needle access of the portal vein is performed clinically at select tertiary centers for measurement of portal pressure gradients in patients with chronic liver disease and sampling of portal venous thrombus to diagnose malignancy. We propose that this novel clinical technique can be applied in research studies to allow blood collection from and profiling of portal and hepatic circulation. In this technical report, we present and highlight the technical aspects, feasibility and safety of EUS - guided portal venous blood collection. As a proof of the concept and the utility of this technique in metabolic research and biomarker assessment and discovery, we present a pilot metabolite profiling study of portal venous blood in a small cohort of patients with cirrhosis and a comparison to a group without cirrhosis. Despite the very small diameter of the endoscopic needle used for the blood collection, the portal samples have the same quality as those collected from systemic circulation, and they can be used for the same downstream applications. Finally, we propose an analytical workflow to screen for promising metabolites that could qualify for further studies to determine their utility as sensitive, early, candidate biomarkers of hepatic fibrosis, portal shunt and hypertension. We hope that this report could stimulate and facilitate the widespread use of EUS-guided techniques for the profiling of portal circulation, which could potentially open a new field of scientific inquiry.

show abstract

“…Up to the present, most of the relative studies have focused on MASLD, alcoholic liver disease, viral hepatitis, and HCC. [10][11][12] However, data on the metabolomic profile of autoimmune liver diseases are scarce. Indeed, only 2 studies with a small number of patients, using NMR [13] or mass spectrometry [14] have investigated the metabolomic profile of AIH in comparison to PBC and healthy controls (HCs).…”

Section: Introductionmentioning

confidence: 99%

“…In this context, the differential metabolomic profile of liver diseases could be used for their diagnosis and to study their pathogenesis. Up to the present, most of the relative studies have focused on MASLD, alcoholic liver disease, viral hepatitis, and HCC 10–12 . However, data on the metabolomic profile of autoimmune liver diseases are scarce.…”

Section: Introductionmentioning

confidence: 99%

NMR-based metabolomic signature: An important tool for the diagnosis and study of pathogenesis of autoimmune hepatitis

Dimou,

Zachou,

Kostara

et al. 2024

Hepatology

View full text Add to dashboard Cite

Background & Aims: Metabolomics are used to predict, diagnose, and monitor metabolic disorders but altered metabolomic signature has also been reported in diverse diseases, including autoimmune disorders. However, the metabolomic profile in autoimmune hepatitis (AIH), has not been investigated in depth. Therefore, we investigated the metabolomic signature of AIH and its significance as a diagnostic and pathogenetic tool. Approach & Results: Metabolites in plasma samples from 50 AIH patients at diagnosis, 43 healthy controls (HC), 72 patients with primary biliary cholangitis (PBC), 26 patients with metabolic dysfunction-associated liver disease (MASLD) and 101 patients with chronic viral hepatitis (CVH) were determined by 1H-NMR spectroscopy. Fifty-two metabolites were quantified, and metabolic pathway analysis was performed. Multivariate analysis revealed that AIH could be differentiated from HC and each of the disease controls (p<0.001). 15 metabolites differentiated AIH from disease controls (PBC+CVH+MASLD) (95% sensitivity and 92% specificity). Ten distinct metabolic pathways were altered in AIH compared to disease controls. The metabolic pathway of branched-chain amino acids (BCAAs) (lower valine, leucine and isoleucine levels and their catabolic intermediates in PBC), methionine (lower methionine, 2-aminobutyrate and 2-hydroxybutyrate levels in PBC), alanine-aspartate-glutamate (lower metabolites in PBC) and that of metabolites associated with gut microbiota (lower choline, betaine, and dimethylamine levels in PBC) were significantly different between AIH and PBC (p<0.01). Conclusions: 1H-NMR spectroscopy could be a promising novel tool to diagnose and study AIH pathogenesis as there is no need of much sample handling, is highly reproducible with high sensitivity and specificity and low cost.

show abstract

What’s in Metabolomics for Alcoholic Liver Disease?

Abstract: Due to their high NPV, NLG and DTEA could be used in conjunction in ALD patients to exclude cirrhosis or a severe disease. If further validated, they could become biomarkers for better management and risk assessment in ALD.

Cited by 13 publications

References 29 publications

Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy

Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy

Endoscopic ultrasound-guided sampling and profiling of portal circulation in human patients for metabolic research studies and biomarker assessment

NMR-based metabolomic signature: An important tool for the diagnosis and study of pathogenesis of autoimmune hepatitis

Contact Info

Product

Resources

About